{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/18680"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/18680","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"DESIGN, SYNTHESIS, AND EVALUATION OF MOLECULAR IMAGING PROBES FOR CATHEPSIN B","abstract":"Cathepsin B is a cysteine protease that is overexpressed in cancers that are likely to metastasize. Molecular imaging can be used to non-invassively detect cathepsin B in vivo in order to characterize cancer progression and treatment response. This thesis describes the development of four different strategies to develop cathepsin B targeted probes. First, an SAR strategy was used to synthesize and test a number of AOMK inhibitors that incorporated iodine. A high affinity (Ki = 180 nM) lead 2.23a was converted to its radioactive analogue [125I]2.23a by optimizing radiolabelling procedures to maximize radiochemical yields (>26%) and radiochemical purities (> 95%). In vivo evaluation showed low tumour uptake (0.05% at 23 h p.i.) due to high in vivo deiodination (thyroid = 20% ID/g at 23 h p.i.). Next, AOMK inhibitors with greater stability were developed using the [ReCO3]+ core either via a direct linkage or a dendrimer platform. The binding affinities of these probes were lower than 2.23a (Ki > 350 nM). A pretargeted approach was then developed that could be used to image cathepsin B in vitro and in vivo. Third, an affinity label was developed using the AOMK warhead linked to TCO giving 4.5 (Ki = 190 nM). A cell assay was developed and intracellular targeting of cathepsin B was observed, something that has not been observed previously with a pretargeted agent in nuclear medicine. Of the five tetrazine based bioorthogonal pairs tested with 4.5, three were sufficient for this approach. The final approach was to use a cathepsin B substrate to link a radiopharmaceutical such as an iodobenzamide used for melanoma imaging. Synthetic strategies were explored to develop the radioactive and non-radioactive analogues. Challenges were encountered during the development of these probes due to stability, which require further optimization.","abstract_html":"Cathepsin B is a cysteine protease that is overexpressed in cancers that are likely to metastasize. Molecular imaging can be used to non-invassively detect cathepsin B in vivo in order to characterize cancer progression and treatment response. This thesis describes the development of four different strategies to develop cathepsin B targeted probes. First, an SAR strategy was used to synthesize and test a number of AOMK inhibitors that incorporated iodine. A high affinity (Ki = 180 nM) lead 2.23a was converted to its radioactive analogue [125I]2.23a by optimizing radiolabelling procedures to maximize radiochemical yields (&gt;26%) and radiochemical purities (&gt; 95%). In vivo evaluation showed low tumour uptake (0.05% at 23 h p.i.) due to high in vivo deiodination (thyroid = 20% ID/g at 23 h p.i.). Next, AOMK inhibitors with greater stability were developed using the [ReCO3]+ core either via a direct linkage or a dendrimer platform. The binding affinities of these probes were lower than 2.23a (Ki &gt; 350 nM). A pretargeted approach was then developed that could be used to image cathepsin B in vitro and in vivo. Third, an affinity label was developed using the AOMK warhead linked to TCO giving 4.5 (Ki = 190 nM). A cell assay was developed and intracellular targeting of cathepsin B was observed, something that has not been observed previously with a pretargeted agent in nuclear medicine. Of the five tetrazine based bioorthogonal pairs tested with 4.5, three were sufficient for this approach. The final approach was to use a cathepsin B substrate to link a radiopharmaceutical such as an iodobenzamide used for melanoma imaging. Synthetic strategies were explored to develop the radioactive and non-radioactive analogues. Challenges were encountered during the development of these probes due to stability, which require further optimization.","abstract_has_math":false,"creators":["Edem, Patricia"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Chemical Biology","school":null,"contributors":[],"advisors":["Valliant, John F."],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016","date_published":"2016","updated_at":"2026-11-18T19:37:11Z","subjects":[],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/17998"],"render_values":[{"text":"https://doi.org/10.71548/17998","href":"https://doi.org/10.71548/17998","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/18680","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/18680","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F18680","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Valliant, John F."]},{"key":"dc:contributor.department","label":"Department","values":["Chemical Biology"]},{"key":"dc:creator","label":"Author","values":["Edem, Patricia"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2016-01-05T20:06:28Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2016-01-05T20:06:28Z"]},{"key":"dc:date.issued","label":"Date","values":["2016"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/18680","https://doi.org/10.71548/17998"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Cathepsin B is a cysteine protease that is overexpressed in cancers that are likely to metastasize. Molecular imaging can be used to non-invassively detect cathepsin B in vivo in order to characterize cancer progression and treatment response. This thesis describes the development of four different strategies to develop cathepsin B targeted probes. First, an SAR strategy was used to synthesize and test a number of AOMK inhibitors that incorporated iodine. A high affinity (Ki = 180 nM) lead 2.23a was converted to its radioactive analogue [125I]2.23a by optimizing radiolabelling procedures to maximize radiochemical yields (>26%) and radiochemical purities (> 95%). In vivo evaluation showed low tumour uptake (0.05% at 23 h p.i.) due to high in vivo deiodination (thyroid = 20% ID/g at 23 h p.i.). Next, AOMK inhibitors with greater stability were developed using the [ReCO3]+ core either via a direct linkage or a dendrimer platform. The binding affinities of these probes were lower than 2.23a (Ki > 350 nM). A pretargeted approach was then developed that could be used to image cathepsin B in vitro and in vivo. Third, an affinity label was developed using the AOMK warhead linked to TCO giving 4.5 (Ki = 190 nM). A cell assay was developed and intracellular targeting of cathepsin B was observed, something that has not been observed previously with a pretargeted agent in nuclear medicine. Of the five tetrazine based bioorthogonal pairs tested with 4.5, three were sufficient for this approach. The final approach was to use a cathepsin B substrate to link a radiopharmaceutical such as an iodobenzamide used for melanoma imaging. Synthetic strategies were explored to develop the radioactive and non-radioactive analogues. Challenges were encountered during the development of these probes due to stability, which require further optimization."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Doctor of Philosophy (PhD)"]},{"key":"dc:title","label":"Title","values":["DESIGN, SYNTHESIS, AND EVALUATION OF MOLECULAR IMAGING PROBES FOR CATHEPSIN B"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Valliant, John F."],"dc:contributor.department":["Chemical Biology"],"dc:creator":["Edem, Patricia"],"dc:date.accessioned":["2016-01-05T20:06:28Z"],"dc:date.available":["2016-01-05T20:06:28Z"],"dc:date.issued":["2016"],"dc:description.abstract":["Cathepsin B is a cysteine protease that is overexpressed in cancers that are likely to metastasize. Molecular imaging can be used to non-invassively detect cathepsin B in vivo in order to characterize cancer progression and treatment response. This thesis describes the development of four different strategies to develop cathepsin B targeted probes. First, an SAR strategy was used to synthesize and test a number of AOMK inhibitors that incorporated iodine. A high affinity (Ki = 180 nM) lead 2.23a was converted to its radioactive analogue [125I]2.23a by optimizing radiolabelling procedures to maximize radiochemical yields (>26%) and radiochemical purities (> 95%). In vivo evaluation showed low tumour uptake (0.05% at 23 h p.i.) due to high in vivo deiodination (thyroid = 20% ID/g at 23 h p.i.). Next, AOMK inhibitors with greater stability were developed using the [ReCO3]+ core either via a direct linkage or a dendrimer platform. The binding affinities of these probes were lower than 2.23a (Ki > 350 nM). A pretargeted approach was then developed that could be used to image cathepsin B in vitro and in vivo. Third, an affinity label was developed using the AOMK warhead linked to TCO giving 4.5 (Ki = 190 nM). A cell assay was developed and intracellular targeting of cathepsin B was observed, something that has not been observed previously with a pretargeted agent in nuclear medicine. Of the five tetrazine based bioorthogonal pairs tested with 4.5, three were sufficient for this approach. The final approach was to use a cathepsin B substrate to link a radiopharmaceutical such as an iodobenzamide used for melanoma imaging. Synthetic strategies were explored to develop the radioactive and non-radioactive analogues. Challenges were encountered during the development of these probes due to stability, which require further optimization."],"dc:description.degree":["Doctor of Philosophy (PhD)"],"dc:identifier.uri":["http://hdl.handle.net/11375/18680","https://doi.org/10.71548/17998"],"dc:language.iso":["en"],"dc:title":["DESIGN, SYNTHESIS, AND EVALUATION OF MOLECULAR IMAGING PROBES FOR CATHEPSIN B"],"dc:type":["Thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:37:11Z"}